Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.56 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.52 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.52 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.48 |
| ▸ | GBA2 | Q9HCG7 | 7/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | UGCG | Q16739 | 2/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | AGL | P35573 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23777202 | 1.00 | SPHK2 (0.56) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| Hydrochloric Acid SCHEMBL27684543 | 0.98 | SPHK2 (0.55) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL7270850 | 0.95 | SPHK2 (0.58) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL23865736 | 0.95 | SPHK2 (0.58) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL23866033 | 0.95 | SPHK2 (0.58) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL11929540 | 0.94 | SPHK2 (0.61) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL11929539 | 0.94 | SPHK2 (0.61) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL1972036 | 0.94 | SPHK2 (0.61) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL11195122 | 0.93 | SPHK2 (0.61) | SPHK2SPHK1S1PR1S1PR3S1PR5 | |
| SCHEMBL11194154 | 0.93 | SPHK2 (0.61) | SPHK2SPHK1S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301192-A1 | Inhibitors of Cyclin Kinase Inhibitor p21 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | US | disclosed |
| EP-2275412-A1 | Indole and benzimidazole derivatives | Novartis Vaccines and Diagnostics, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2001014381-A1 | ETHER DERIVATIVES OF PYRROLO[1,2-A]QUINOXALINES, METHOD FOR PRODUCING THEM AND THEIR USE IN THERAPY | UNIVERSITE DE CAEN BASSE-NORMANDIE (FR) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301192-A1 | Inhibitors of Cyclin Kinase Inhibitor p21 | CDKN1A, CCNI, CDK2 | SPHK2 772/4885SPHK1 1002/4885S1PR1 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.